




Australian Government  
Department of Health and Ageing

# Screening Monograph No.5/2009

## BreastScreen Australia Evaluation

## Participation and Performance Trends

June 2009



## **BreastScreen Australia Evaluation – Participation and Performance Trends – June 2009**

ISBN: 978-1-7421-005-0

Online ISBN: 978-1-7421-006-7

Publications Number: P3-6010

### **Copyright Statements:**

#### **Paper-based publications**

(c) Commonwealth of Australia 2009

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney-General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>

#### **Internet sites**

(c) Commonwealth of Australia 2009

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the *Copyright Act 1968*, all other rights are reserved. Requests and inquiries concerning reproduction and rights should be addressed to Commonwealth Copyright Administration, Attorney-General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>

# CONTENTS

<b>Acknowledgments</b>	<b>iv</b>
<b>Abbreviations</b>	<b>vi</b>
<b>Symbols</b>	<b>vi</b>
<b>Introduction</b>	<b>1</b>
Background	1
Purpose	2
Scope	3
Statistical significance	4
Key findings	5
Participation and rescreening	5
Cancer detection	6
Morbidity	8
Screening pathway flowcharts	10
<b>Performance indicators</b>	<b>13</b>
Trends in BreastScreen Australia Program performance indicators	13
Indicator 1 Participation	13
Participation in BreastScreen Australia	14
Participation by population subgroup	14
Trends in participation by population subgroup	15
Indicator 2 Detection of invasive cancers	42
Trends in detection of invasive cancers by screening round	42
Trends in detection of invasive cancers by population subgroup	48
Indicator 3 Sensitivity	61
3a Interval cancers	61
Trends in interval cancers by screening round	62
3b Program sensitivity	70
Trends in program sensitivity by screening round	70

Indicator 4 Ductal carcinoma in situ	74
Trends in detection of DCIS by screening round	75
Trends in detection of DCIS by population subgroup	77
Indicator 5 Recall to assessment	85
Trends in recall to assessment by screening round and state and territory	85
Indicator 6 Rescreening	90
Trends in rescreening by screening round and state and territory	90
Trends in rescreening within screening intervals	95
Indicator 7 Incidence	99
Trends in incidence	99
Indicator 8 Mortality	102
Trends in mortality	102
<b>Morbidity</b>	<b>105</b>
Trends in rate of technical repeat performed	107
Waiting times	112
Time between screening and result	112
Trends in time between screening and result	112
Time between screening and assessment	121
Trends in time between screening and assessment	122
Invasive assessment procedures	134
Trends in invasive assessment procedures	135
Fine needle aspiration	140
Core biopsy	143
Invasive assessment results	146
Trends in invasive assessment results	147
Accuracy in predicting cancer status	153
Preoperative diagnosis rate	158
Trends in preoperative diagnosis rate	158
National Accreditation Standards for FNA cytology and core biopsy	162
Trends in National Accreditation Standards for FNA and core biopsy	163
Inadequate/miss rates	164
False negative rates	165

False positive rates	165
Sensitivity	167
Positive predictive values	168
<b>Appendix A: Supplementary tables and standards</b>	<b>170</b>
Indicator 1 Participation	170
Indicator 2 Detection of invasive cancers	172
Indicator 3 Sensitivity	188
Indicator 4 DCIS	193
Indicator 5 Recall to assessment	201
Indicator 6 Rescreening	207
Indicator 7a Incidence of breast cancer	208
Indicator 7b Incidence of ductal carcinoma in situ	214
Indicator 8 Mortality	216
Technical repeat status	219
Time between screening and result	224
Time between screening and assessment	227
Invasive assessment procedure	230
Standards for FNA cytology and core biopsy	244
Inadequate/miss rates	244
False negative rates	245
False positive rates	245
Sensitivity	247
Positive predictive values	249
<b>Appendix B: Summary of BreastScreen Australia performance objectives for performance indicators</b>	<b>250</b>
<b>Appendix C: Data and statistical issues</b>	<b>252</b>
<b>Glossary</b>	<b>259</b>
<b>References</b>	<b>263</b>
<b>List of tables</b>	<b>265</b>
<b>List of figures</b>	<b>275</b>

# ACKNOWLEDGMENTS

The BreastScreen Australia Program is funded by the Australian and state and territory governments. This analysis was undertaken by the Cancer and Screening Unit of the Australian Institute of Health and Welfare in collaboration with the Australian Department of Health and Ageing.

This document was prepared by Ms Christine Sturrock, Ms Edith Christensen, Ms Jane Zhou, Dr Alison Budd, Mr David Meere, Ms Chun Chen and Mr John Harding. Members of the BreastScreen Australia Evaluation Advisory Committee (EAC)—Professor David Roder, as lead sponsor, and supporting sponsors Professor Dallas English, Dr Frida Cheok and Ms Valerie Lang—provided technical advice to inform the project. Ms Julianne Quaine, Ms Alex Lloyd and Ms Gillian Barber provided project leadership as members of the BreastScreen Australia Evaluation Taskforce at the Department of Health and Ageing. Technical advice on the BreastScreen Australia Program and additional assistance with this report were provided by Mr Nathan Dunn.

Thanks are extended to the following state and territory program and data managers for providing the data and overall assistance in the production of this report. Thanks are also extended to all state and territory cancer registries, which are the source of data on breast cancer incidence (through the National Cancer Statistics Clearing House) and data on ductal carcinoma in situ.

## BreastScreen Australia

### **New South Wales**

Mr Mark Costello  
Ms Gordana Culjak  
Mr Arthur Hung

### **Victoria**

Ms Onella Stagoll  
Ms Suzen Maljevac  
Ms Genevieve Chappell  
Ms Karen Winch

### **Queensland**

Ms Jennifer Muller  
Mr Nathan Dunn  
Ms Julia Gray

### **Western Australia**

Dr Liz Wylie  
Ms Jan Tresham

### **South Australia**

Ms Lou Williamson  
Ms Penny Iosifidis  
Ms Ada Childs

### **Tasmania**

Ms Gail Raw  
Mr Dylan Sutton

### **Australian Capital Territory**

Ms Helen Sutherland  
Mr Phillip Crawford

### **Northern Territory**

Ms Chris Tyzack  
Mr Guillermo Enciso

## BreastScreen Australia Evaluation Advisory Committee

Member	Affiliation	Role
Dr Helen Zorbas	Director National Breast and Ovarian Cancer Centre	Chair and Australian expert
Dr Frida Cheok	Consultant	Australian expert
Professor David Currow	Chief Executive Officer Cancer Australia	Cancer Australia representative
Professor Dallas English	Director Centre for Molecular, Environmental, Genetic and Analytical Epidemiology The University of Melbourne	Australian expert
A/Professor Harry de Koning	Professor of Screening Evaluation  Department of Public Health Erasmus Medical Centre The Netherlands	International expert
Ms Valerie Lang AM		Consumer Representative
Mr David Learmonth	Deputy Secretary Department of Health and Ageing	Department of Health and Ageing representative
Ms Jennifer Muller	Director Cancer Screening Services Unit Queensland Health	Jurisdictional member (large jurisdictions)
Clinical A/Professor Jonathan Osborne	State Radiologist BreastScreen Queensland	Australian expert
Ms Julietta Patnick	Director The National Health Service (NHS) Cancer Screening Programs	International expert
Professor David Roder	Head of Centre for Cancer Control research; and Associate Director of the Cancer Epidemiology Centre, Cancer Council of South Australia	Jurisdictional member (small jurisdictions)
Ms Venessa Tripp		Consumer representative
Dr Madeleine Wall	Clinical Leader, BreastScreen Aotearoa, National Screening Unit, New Zealand	Observer

## ABBREVIATIONS

ABS	Australian Bureau of Statistics
ACT	Australian Capital Territory
AIHW	Australian Institute of Health and Welfare
ASGC	Australian Standard Geographical Classification
ASR	age-standardised rate
ASR(A)	age-standardised rate, standardised to the Australian 2001 Population
CI	confidence interval
DoHA	Australian Government Department of Health and Ageing
DCIS	ductal carcinoma in situ
ERP	estimated resident population
ICD	International Classification of Diseases
IRSD	Index of Relative Socioeconomic Disadvantage
NAS	National Accreditation Standards
NQMC	National Quality Management Committee
NSW	New South Wales
NT	Northern Territory
Qld	Queensland
SA	South Australia
Tas	Tasmania
Vic	Victoria
WA	Western Australia

## SYMBOLS

..	not applicable
≤	less than or equal to
<	less than
>	more than